Equities

Lotus Eye Hospital and Institute Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
LOTUSEYE:NSI

Lotus Eye Hospital and Institute Ltd

Actions
Health CareHealth Care Providers
  • Price (INR)117.51
  • Today's Change-6.18 / -5.00%
  • Shares traded42.24k
  • 1 Year change+88.77%
  • Beta0.8749
Data delayed at least 15 minutes, as of Feb 20 2026 07:57 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Lotus Eye Hospital and Institute Limited is an India-based company, which is engaged in the business of healthcare activities. The Company is engaged in the field of ophthalmology (eye) and its related operations. It resolves a range of eye problems, such as refractive, cataract, cornea infections, ocular prosthesis, orbit and oculoplasty, glaucoma, keratoconus, computer vision syndrome, neuro ophthalmology, retinal disease/diabetic eye care, UVEA and ocular inflammation, zyoptix-ultimate, and binocular vision. The Company provides various treatments, suchas ReLEx SMILE, Touchfree Laser, Lasik Eye Surgery, Epi-LASIK, Intralase, Supracor, Robotic Femto Laser Cataract Surgery (LRCS), Phacoemulsification, Paediatric Eye Care and Squint Surgery, and Micro Incision Cataract Surgery (MICS). The Company operates in various locations, such as Sitra, Coimbatore; RS Puram, Coimbatore; Salem; Tirupur; Mettupalayam; Kochi; Mulanthuruthy; Saravanampatty, and Karur.

  • Revenue in INR (TTM)503.15m
  • Net income in INR6.74m
  • Incorporated1997
  • Employees336.00
  • Location
    Lotus Eye Hospital and Institute Ltd770/12 Avinashi Road, Civil Aerodrome post,COIMBATORE 641014IndiaIND
  • Phone+91 4 224229999
  • Fax+91 4 222627193
  • Websitehttps://www.lotuseye.org/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Nephro Care India Ltd676.68m33.97m1.31bn334.0035.952.3717.441.942.212.2144.3133.621.0111.2625.362,025,991.005.07--6.22--72.88--5.02--2.2417.170.00--69.04---17.51------
Maitreya Medicare Ltd459.98m832.35k1.42bn--1,700.734.5085.533.080.12280.122867.8846.430.956314.003.26--0.1732--0.2321--79.87--0.1812--1.921.500.1174---2.31---36.95------
Lotus Eye Hospital and Institute Ltd503.15m6.74m2.57bn336.00358.074.2475.825.110.34540.345424.9629.150.71076.8633.51--0.95193.901.074.3148.2452.201.345.680.90391.040.0751--2.814.09-74.63-7.0314.81--
Data as of Feb 20 2026. Currency figures normalised to Lotus Eye Hospital and Institute Ltd's reporting currency: Indian Rupee INR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.